Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

被引:14
|
作者
Topp, Max S. [1 ]
Stein, Anthony S. [2 ]
Goekbuget, Nicola [3 ]
Horst, Heinz-August [4 ]
Boissel, Nicolas [5 ]
Martinelli, Giovanni [6 ]
Kantarjian, Hagop [7 ]
Brueggemann, Monika [8 ]
Chen, Yuqi [9 ]
Zugmaier, Gerhard [10 ]
机构
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] City Hope Med Ctr, Gehr Leukemia Ctr, Duarte, CA USA
[3] Univ Klinikum, Med Klin Hamatol Onkol Rheumatol Infektiol 3, Frankfurt, Germany
[4] Univ Klinikum Schleswig Holstein, Klin Innere Med 2, Kiel, Germany
[5] Hop St Louis, Unite Hematol Adolescents & Jeunes Adultes, Paris, France
[6] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Sci Directorate, Meldola, FC, Italy
[7] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[8] Univ Klinikum Schleswig Holstein, Sekt Hamatol Spezialdiagnost, Klin Innere Med 2, Kiel, Germany
[9] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
[10] Amgen Res Munich GmbH, Global Dev, Munich, Germany
来源
CANCER MEDICINE | 2021年 / 10卷 / 08期
关键词
acute lymphoblastic leukemia; BiTE® blinatumomab; salvage; stem cell transplant;
D O I
10.1002/cam4.3731
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Blinatumomab is a BiTE(R) immuno-oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). To assess the efficacy and safety of blinatumomab as first salvage versus second or later salvage in patients with r/r BCP ALL. Patient-level pooled data were used for this analysis. In total, 532 adults with r/r BCP ALL treated with blinatumomab were included (first salvage, n = 165; second or later salvage, n = 367). Compared with patients who received blinatumomab as second or later salvage, those who received blinatumomab as first salvage had a longer median overall survival (OS; 10.4 vs. 5.7 months; HR, 1.58; 95% CI, 1.26-1.97; P < .001) and relapse-free survival (10.1 vs. 7.3 months; HR, 1.38; 95% CI, 0.98-1.93; P = .061), and higher rates of remission (n = 89 [54%] vs. n = 150 [41%]; odds ratio, 0.59; 95% CI, 0.41-0.85; P = .005), minimal residual disease response (n = 68 [41%] vs. n = 118 [32%]), and allogeneic hematopoietic stem cell transplant (alloHSCT) realization (n = 60 [36%] vs. n = 88 [24%]), and alloHSCT in continuous remission (n = 33 [20%] vs. n = 52 (14%]). In a subgroup analysis, there was no apparent effect of prior alloHSCT on median OS in either salvage group. The safety profile of blinatumomab was generally similar between the groups; however, cytokine release syndrome, febrile neutropenia, and infection were more frequent with second or later salvage than with first salvage. In this pooled analysis, the logistic regression analyses indicated greater benefit with blinatumomab as first salvage than as second or later salvage, as evident by the longer median OS, longer median RFS, and higher rates of remission. Overall, blinatumomab was beneficial as first salvage and as second or later salvage, but the effects were favorable as first salvage. Aims Materials & Methods Results Discussion Conclusion
引用
收藏
页码:2601 / 2610
页数:10
相关论文
共 50 条
  • [1] Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia
    Dombret, Herve
    Topp, Max S.
    Schuh, Andre C.
    Wei, Andrew H.
    Durrant, Simon
    Bacon, Christopher Larry
    Qui Tran
    Zimmerman, Zachary
    Kantarjian, Hagop
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2214 - 2222
  • [2] Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Kobayashi, Yukio
    Oh, Iekuni
    Miyamoto, Toshihiro
    Lee, Won-Sik
    Iida, Hiroatsu
    Minami, Hironobu
    Maeda, Yoshinobu
    Jang, Jun Ho
    Yoon, Sung-Soo
    Yeh, Su-Peng
    Tran, Qui
    Morris, Joan
    Franklin, Janet
    Kiyoi, Hitoshi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (03) : 311 - 318
  • [3] Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Goekbuget, Nicola
    Kantarjian, Hagop M.
    Brueggemann, Monika
    Stein, Anthony S.
    Bargou, Ralf C.
    Dombret, Herve
    Fielding, Adele K.
    Heffner, Leonard
    Rigal-Huguet, Francoise
    Litzow, Mark
    O'Brien, Susan
    Zugmaier, Gerhard
    Gao, Shan
    Nagorsen, Dirk
    Forman, Stephen J.
    Topp, Max S.
    BLOOD ADVANCES, 2019, 3 (20) : 3033 - 3037
  • [4] Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab
    Queudeville, Manon
    Handgretinger, Rupert
    Ebinger, Martin
    ONCOTARGETS AND THERAPY, 2017, 10 : 3567 - 3578
  • [5] Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Queudeville, Manon
    Schlegel, Patrick
    Heinz, Amadeus T.
    Lenz, Teresa
    Doering, Michaela
    Holzer, Ursula
    Hartmann, Ulrike
    Kreyenberg, Hermann
    von Stackelberg, Arend
    Schrappe, Martin
    Zugmaier, Gerhard
    Feuchtinger, Tobias
    Lang, Peter
    Handgretinger, Rupert
    Ebinger, Martin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (04) : 473 - 483
  • [6] Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults
    Zhao, Yaqi
    Aldoss, Ibrahim
    Qu, Chunxu
    Marcucci, Guido
    Stein, Anthony S.
    Bhatia, Ravi
    Mullighan, Charles G.
    Forman, Stephen J.
    Roberts, Kathryn G.
    BLOOD, 2018, 132
  • [7] Inotuzumab Ozogamicin Salvage Monotherapy for the Treatment of Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S192 - S193
  • [8] FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia
    Pulte, E. Dianne
    Vallejo, Jonathon
    Przepiorka, Donna
    Nie, Lei
    Farrell, Ann T.
    Goldberg, Kirsten B.
    McKee, Amy E.
    Pazdur, Richard
    ONCOLOGIST, 2018, 23 (11): : 1366 - 1371
  • [9] Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Anthony Stein
    Janet L. Franklin
    Victoria M. Chia
    Deborah Arrindell
    William Kormany
    Jacqueline Wright
    Mandy Parson
    Hamid R. Amouzadeh
    Jessica Choudhry
    Guiandre Joseph
    Drug Safety, 2019, 42 : 587 - 601
  • [10] The Usefulness of Blinatumomab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Review
    Watakabe, Mai
    Arakawa, Yuki
    Irikura, Tomoya
    Honda, Mamoru
    Mitani, Yuichi
    Oshima, Koichi
    Watanabe, Atsuko
    Mori, Makiko
    Fukuoka, Kohei
    Koh, Katsuyoshi
    PEDIATRIC BLOOD & CANCER, 2021, 68